• Skip to main content

DistilNFO Health

Health Sector News from India

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

India in talks with Russia on Sputnik-V covid vaccine: Health Ministry

Share:

August 26, 2020

Highlights on this story:
  • Some initial information about Russia's Sputnik-V vaccine has been shared with India, says health ministry
  • At present three Covid-19 vaccines are 'ahead in the race in India,' adds ICMR

Amid the race to develop a vaccine against the novel coronavirus, Health Ministry today said that India is in conversation with Russia on lines of Sputnik-V covid-19 vaccine, which was earlier launched by Russian President Vladimir Putin.

“As far as Sputnik-5 vaccine is concerned, India and Russia are in communication. Some initial information has been shared,” said said Rajesh Bhushan, Secretary, Union Health Ministry.

Russia had recently registered “world’s first Covid-19 vaccine” and is now in the phase III trial of the vaccine, which involved more than 40,000 people at more than 45 medical centres around Russia, the TASS news agency reported earlier.

According to an earlier report, Russia is looking for a partnership with India for producing Covid-19 vaccine, Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF).

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Dmitriev said several nations are interested in the production of the vaccine from countries in Latin America, Asia and the Middle East.

“The production of the vaccine is a very important issue. Currently, we are looking for a partnership with India. We believe that they are capable of producing the Gamaleya vaccine and it is very important to say that those partnerships to produce the vaccine will enable us to cover the demand that we have,” he said.

He also said Russia is looking forward to international cooperation.

“We are going to do clinical trials not just in Russia but also in the UAE, Saudi Arabia, probably in Brazil and India. We are planning to produce the vaccine in more than five countries and there is a very high demand from Asia, Latin America, Italy and other parts of the world regarding the delivery of the vaccine,” he added.

Dubbed as Sputnik V, the vaccine is developed by Gamaleya Research Institute and the Russian defence ministry. Russia registered the vaccine after less than two months of human testing. The results of initial trials have not been made public yet.

Earlier, the Indian Medical Research Institute (ICMR)’s director general Balram Bhargava had said, “Russia has fast tracked a vaccine which has been successful in its early phases. They have fast tracked its development.”

Apart from that, the ministry also mentioned that India has also ramped up the development of its Covid-19 vaccine. At present three COVID-19 vaccines are “ahead in the race in India,” said Dr Bhargava.

The Serum Institute’s vaccine is in phase 2(B) and phase 3 trials and Bharat Biotech and Zydus Cadila’s vaccines have completed phase 1 trial, informed Dr Bhargava.

Meanwhile, the Covid-19 vaccine being developed by the University of Oxford and AstraZeneca could be put before regulators this year if scientists are able to gather enough data, said the director of the Oxford Vaccine Group.

In terms of the country’s Covid-19 situation, the ministry said that while tests for detection of Covid-19 have increased exponentially, there has been steady decline in country’s positivity rate.

“Recovered Covid-19 cases are 3.4 times the number of active cases in the country,” said a ministry official.

For the first time, country’s active cases of Covid-19 have reduced by 6,423 within a span of 24 hours, said Secretary, Union Health Ministry. Active cases are only 22.2% of the total cases. The recovery rate is now more than 75%, he said.

Source: Livemint

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

Related Posts

  • Medical Debt a Major Cause of Poverty in IndiaMedical Debt a Major Cause of Poverty in India
  • ‘We’re Adding One Hospital in India Every Year’‘We’re Adding One Hospital in India Every Year’
  • Kerala Government-owned Keltron Switches to Medical Devices, to Launch Four Products in Two WeeksKerala Government-owned Keltron Switches to Medical Devices, to Launch Four Products in Two Weeks
  • Healthcare can be India’s Next IT Sector, says Kiran
  • Ramco Unveils Touchless Attendance System That Records TemperatureRamco Unveils Touchless Attendance System That Records Temperature
  • Opinion | The Surveillance India Actually Needs to Quell the VirusOpinion | The Surveillance India Actually Needs to Quell the Virus
  • Chandigarh Launches Digital Health Card, 4K Register on Day 1Chandigarh Launches Digital Health Card, 4K Register on Day 1
  • Health Partnership with India Goes ‘Beyond’ Vaccines, Says UK Envoy Philip BartonHealth Partnership with India Goes ‘Beyond’ Vaccines, Says UK Envoy Philip Barton

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications